Y-mAbs Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Y-mAbs Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Y-mAbs Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Y-mAbs Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Y-mAbs Therapeutics Inc (Y-mAbs), a subsidiary of SERB Pharmaceuticals, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The company's products include DANYELZA for the treatment of relapsed or refractory high-risk neuroblastoma. Y-mAbs pipeline includes GD2-SADA-177Lu-Proteus, 89Zr-DFO-naxitamab, CD38-SADA, Y-ST01-PRIT, Y-ST01-Dx, Y-ST02-PRIT, Y-ST03-PRIT, Y-ST03-Dx, Y-ST04-PRIT, Y-ST05-PRIT, and Y-ST06-PRIT for the indication of recurrent or refractory small cell lung cancer, sarcoma, malignant melanoma, and high-risk neuroblastoma, relapsed or refractory non-Hodgkin lymphoma, colorectal cancer, prostate cancer and solid tumors. The company operates in the US and Denmark. Y-mAbs is headquartered in Princeton, New Jersey, the US
Headquarters
United States of America
Address
Suite 301, 202 Carnegie Center, Princeton, New Jersey, 08540
Website
www.ymabs.com
Telephone
1 646 8858505
No of Employees
107
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$87.7M
Y-mAbs Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| DANYELZA (naxitamab-gqgk): Relapsed or Refractory High-Risk Neuroblastoma (HRNB) | Danyelza |
| Pipeline | |
| GD2-SADA-177Lu-Proteus: Recurrent/Refractory Small Cell Lung Cancer (SCLC), Sarcoma, Malignant Melanoma, and High-Risk Neuroblastoma | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In Sep, the company was acquired by SERB Pharmaceuticals. |
| 2024 | Contracts/Agreements | In November, the company entered into a license and distribution agreement with Nobelpharma Co., Ltd. to develop and commercialize DANYELZA to treat patients with relapsed/refractory high-risk neuroblastoma. |
| 2023 | Regulatory Approval | In October, the company announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application for CD38-SADA. |
Competitor Comparison
| Key Parameters | Y-mAbs Therapeutics Inc | BeOne Medicines AG | United Therapeutics Corp | Recordati UK Ltd | MacroGenics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United Kingdom | United States of America |
| City | Princeton | Basel | Silver Spring | Hemel Hempstead | Rockville |
| State/Province | New Jersey | Basel-Stadt | Maryland | England | Maryland |
| No. of Employees | 107 | 12,000 | 1,400 | 76 | 293 |
| Entity Type | Private | Public | Public | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vanessa Wolfeler | Chief Executive Officer - SERB Pharmaceuticals | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer